In today’s clinical research environment, biosimilars present long-term study opportunities for investigators. Citeline® has reported 350 biosimilars in development in 2015, which is an increase of 23% over the past year. Join us for this webinar to learn more about the biosimilar pipeline and how the demand for investigators across a wide range of therapy areas could be an opportunity waiting for sites like you! Our speakers will explain biosimilars (not to be confused with ‘generics’) and how they can increase access to biologic therapies for patients around the world. Large clinical trials are required to bring biosimilars to market, presenting immediate and long-term benefits for both sites and their patients.
Nigel Rulewski, MD, Head, Biosimilars Center of Excellence, Quintiles
Tracy Stewart, MBA, Director, Site & Patient Networks, Quintiles